Levetiracetam (LEV) is a medication that has been used to treat a variety of neurological conditions, including epilepsy, bipolar disorder, and anxiety. It is a relatively new drug, first approved by the US Food and Drug Administration (FDA) in 1999. While LEV has been found to be effective in treating these conditions, it has also been associated with a number of side effects. This article will explore the unintended consequences of LEV, including potential side effects, drug interactions, and long-term health risks.
Levetiracetam (LEV) is an anticonvulsant medication that is used to treat epilepsy, bipolar disorder, and anxiety. It is a relatively new drug, first approved by the FDA in 1999. LEV works by stabilizing electrical activity in the brain, which helps to reduce seizures and other symptoms associated with these conditions. It is available in tablet, solution, and suspension forms, and is typically taken twice a day.
Like all medications, LEV can cause side effects. The most common side effects of LEV include drowsiness, dizziness, headache, nausea, and vomiting. It can also cause blurred vision, dry mouth, and loss of appetite. These side effects are usually mild and may go away as your body adjusts to the medication. More serious side effects of LEV include difficulty breathing, swelling of the face, throat, or tongue, rash or hives, and seizures.
LEV can interact with other medications, so it is important to tell your doctor about any other medications you are taking. For example, LEV can interact with anticoagulants (blood thinners), such as warfarin, and can increase the risk of bleeding. It can also interact with other anticonvulsants, such as phenytoin, and can increase the risk of seizures. It is also important to tell your doctor if you are taking any herbal supplements, as they can interact with LEV and cause side effects. For example, ginkgo biloba can increase the risk of bleeding, and St. John’s wort can increase the risk of seizures.
There is limited research on the long-term effects of LEV, but some studies suggest that it may increase the risk of certain health conditions. For example, one study found that long-term use of LEV may increase the risk of bone fractures. Another study found that long-term use of LEV may increase the risk of depression and suicidal thoughts. It is important to speak with your doctor about any potential long-term risks of LEV before taking it.
Levetiracetam (LEV) is a medication that is used to treat a variety of neurological conditions, including epilepsy, bipolar disorder, and anxiety. While it can be effective in treating these conditions, it can also cause side effects and interact with other medications. It is also important to be aware of the potential long-term health risks associated with LEV, as some studies suggest that it may increase the risk of certain health conditions. It is important to talk to your doctor about any potential risks before taking LEV.
1.
The combination of nitedanib and prednisone reduces exacerbations of pulmonary diseases in radiative pneumonitis
2.
In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.
3.
A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.
4.
Lung nodules seen in a high percentage of non-smokers
5.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
1.
Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma
2.
Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology
3.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
4.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
5.
Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation